Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study.
Adams CJ, Shapera S, Ryerson CJ, Assayag D, Johannson KA, Fell CD, Morisset J, Manganas H, Kolb M, Hambly N, Cox G, Khalil N, Marcoux V, Wilcox PG, To T, Sadatsafavi M, Halayko AJ, Gershon A, Garlick K, Fisher JH.
Adams CJ, et al. Among authors: cox g.
Respir Med. 2022 Jan;191:106722. doi: 10.1016/j.rmed.2021.106722. Epub 2021 Dec 23.
Respir Med. 2022.
PMID: 34959146
Free article.